Targets › CD8
2 programs from 2 companies in 3 trials: 3 Phase 1; Oncology; next expected readout May 2027.
Open in Phaseline: the race on CD8, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Antithymocyte globulin (ATG) Polyclonal antibody targeting T lymphocytes; immunosuppressant | CTLA4, CD2, CD3, CD4, CD8 | Phase 1 | Myeloid Diseases; Hematologic Malignancies | May 2027 |
| AstraZeneca | AZD6621 T cell-engaging antibody targeting STEAP2, CD3, and CD8 | STEAP2, CD3, CD8 | Phase 1 | Prostate Cancer | Mar 2029 |
Myeloid Diseases (1) Hematologic Malignancies (1) Prostate Cancer (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.